Advertisement

Topics

Companies Related to "A Pilot Study of Tumor-Specific Peptide Vaccination and IL-2 With or Without Autologous T Cell Transplantation in Recurrent Pediatric Sarcomas" [Most Relevant Company Matches] RSS

16:16 EST 16th February 2019 | BioPortfolio

Here are the most relevant search results for "A Pilot Study of Tumor-Specific Peptide Vaccination and IL-2 With or Without Autologous T Cell Transplantation in Recurrent Pediatric Sarcomas" found in our extensive corporate database of over 50,000 company records.

Showing "Pilot Study Tumor Specific Peptide Vaccination With Without" Companies 1–25 of 2,300+

Relevant

APO-T B.V. and LinXis B.V.

APO-T is a biopharmaceutical company focused on the development and commercialization of proprietary biotherapeutics for oncology. APO-T has developed fully-human antibodies and antibody fragments that target any tumor cell that expresses a MAGE-A peptide in the context of MHC-1. Many different kinds of tumors expose this MAGE-MHC-1 peptide complex. They a...


RESprotect GmbH

RESprotect GmbH from Dresden develops drugs that prevent induction of chemoresistance of tumor cells and enhance their chemosensitivity. This concept is worldwide without concurrence. The first drug RP101 significantly extended survival time of pancreas cancer patients in a clinical pilot study.

Advanced ChemTech Incorporated

Advanced ChemTech offers a wide selection of fine chemical products for the Peptide and Pharmaceutical industries.We offer, as our main focus, custom peptide and unusual amino acid synthesis. From our pilot plant, we offer customers scale-up services and bulk pricing on a broad range of organic chemicals. We also offer a catalog of over 1,100 amino acids, resins, peptides and reagents.Our 20 years...


Peptide Resource Page

Welcome to the Peptide Resource Page (PRP). Founded in 2004, the PRP is designed to help researchers and educators navigate through the maze of peptide related websites. Search our pages to find peptide synthesis reagents, custom peptide suppliers, peptide property calculators, and much more. We also maintain an updated list of providers of peptide synthesizers and peptide sequencing services. The...

Cytheris SA

Cytheris is a privately held clinical-stage biopharmaceutical company focused on research and development of therapies for immune modulation.  These drugs aim at reconstituting and enhancing the immune system of patients suffering from cancer, chronic viral or bacterial infections such as HIV, HCV, and HBV or lympho-depleting treatments such as chemotherapy, radiotherapy, bone marrow transp...

Tyrogenex

Tyrogenex is developing X-82, as a targeted therapeutic for ophthalmological diseases and solid tumors. Preliminary data from a phase 1/2 pilot study show that X-82 is well tolerated and did not exhibit any dose-limiting toxicity during the study.

Quality Controlled Biochemicals

Quality Controlled Biochemicals has over 10 years of experience as a full-service supplier of Custom Peptides and Custom Antibodies to scientists in academia and the bio-pharmaceutical industry. We have worked with researchers on the lipidation of peptides for use in vaccines or as drug delivery systems in intact cells. Our multi-phosphorylated peptides are used as reagents in protein phosphorylat...

ALK-Abelló

ALK-Abelló is the world-leading producer of pharmaceuticals for specific allergy vaccination. Not only do our allergy vaccines treat the allergic symptoms, but also the underlying causes of allergy – and at the same time they prevent asthma.ALK-Abelló has been active in allergy vaccination since 1923. In recent years, we have pursued a product development strategy of extending the current mar...

ImmunoBiology Limited (ImmBio)

Limited [ImmBio] is a biotechnology company specialising in the treatment of infectious diseases and cancer. ImmBio's approach is to apply advances in the emerging science of Immunobiology to the development of treatments for infections diseases and cancer. Immbio is developing a proprietary vaccine technology based on these advances. The platform technology is called HspC™ vaccination. HspC...

Immunetics, Inc.

Immunetics has pioneered the use of the C6 peptide, a 26-amino acid sequence within the Borrelia membrane protein VlsE. This is the first truly specific and sensitive marker for infection with the Borrelia burgdorferi spirochete. The C6 peptide sequence is highly antigenic, generating an immune response in nearly all human cases soon after infection, and it is specific to Borrelia strains causing ...

Pilot Pharmaceuticals

Pilot Pharmaceuticals develops novel products to treat CNS disorders with unmet medical need and substantial market size. The Company takes candidate drugs from an early discovery stage into clinical development.Pilot Pharmaceuticals will license its products to pharmaceutical companies, allowing them to complete the clinical development, gain regulatory approval and market the product.Pilot Pharm...

Ardea Biosciences, Inc.

Ardea Biosciences, Inc., of San Diego, California, is a biotechnology company focused on the development of small-molecule therapeutics for the treatment of gout, cancer and human immunodeficiency virus (HIV). RDEA594, our lead product candidate for the treatment of hyperuricemia and gout, is a selective URAT1 transporter inhibitor in Phase 2 clinical development. Our next-generation URAT1 inhib...

ALK Abello A/S

ALK Abello develops, produces and distributes effective, innovative products for the diagnosis, prevention, relief of allergic symptoms and cure of allergies.ALK Abello's R&D activities focus on specific allergy diagnosis and vaccination.

Sinopep Pharmaceutical Inc.

Sinopep Pharmaceutical Inc., located in HangzhouCChina, specializes in the research and production of generic and custom peptides for pharmaceutical application. Our comprehensive array of products and services makes us the leader in its field in China. We have owned a well-equipped R&D center and one API manufacturing basis. With the synthesis technology of solid phase peptide synthesis(SPPS) ...

Blaze Bioscience, Inc.

Blaze Bioscience, Inc. is a Seattle-based, privately-held biotechnology company dedicated to developing products that assist surgeons in their quest to improve the lives of cancer patients. The company was founded in 2010 to develop and commercialize the Tumor Paint technology. The first Tumor Paint product candidate, CyTP 007, is under development for bra...

AdnaGen AG

AdnaGen's diagnostics detect circulating tumor cells in tumor patients. Because tumor cells survive only hours in the bloodstream, there must be an active source, e.g. a relapse or a metastasis. Therefore, the presence of circulating tumor cells is an unfavorable indicator for the progress of the tumor disease. AdnaGen's proprietary 'combination-of-combinations-principle' allows the reliable and v...

CellAct Pharma

CellAct Pharma is focused on the development of innovative therapeutics for the treatment of cancers. CellAct‘s drug candidates target and modulate human molecules that have specific functions in tumor growth. A first small molecule compound, CAP7.1 is currently in a clinical Phase II study for the treatment of solid cancers. CellAct has received a €0.7...

i3 Statprobe

Because we're strong in every area, you can outsource an entire study to i3 Statprobe, or outsource, for example, only the statistical programming for a single study. Or you can outsource only the statistical programming for every study. Use us any way you want to, we encourage it. For example, we'll provide a dedicated team of specialists (say, data coordinators or statistical programmers) to wor...

Pharmacon Research GmbH

Pharmacon Research is an independent contract research organization (CRO) with headquarters in Berlin and clinical sites in Prague, Warsaw, Bratislava and Budapest. Founded in 1992 by the management of a successful Phase I unit, Pharmacon Research focuses on specific Phase I studies in patients and symptomatic subjects and on early Phase II studies (dose finding, proof of concept). Irrespective of...

Affigen

Affigen (www.affigen.com) develops tumor-identifying therapeutics that target cell lineage-specific tumor proteins in certain incurable cancers. The Company's growing team houses deep expertise in immuno-oncology, mass-personalized biomolecular engineering and complex therapeutic development, and is working to deliver a new class of therapeutics that ...

Cytovax Biotechnologies Incorporated

Cytovax Biotechnologies Inc. is a biotechnology company focused on the development of novel approaches for the prevention and treatment of infectious diseases.Cytovax is developing new, effective weapons in the fight against infectious diseases. Cytovax's products act through a mechanism that is different from that of current anti-infectives, such as antibiotics, which are designed to kill bacteri...

PeptiDream Inc.

PeptiDream Inc. is a public (Tokyo Stock Exchange Mothers 4587) biopharmaceutical company founded in 2006 employing our proprietary Peptide Discovery Platform System (PDPS), a state-of-the-art highly versatile peptide generation and selection platform which enables the production of highly diverse (trillions) non-standard peptide libraries with high effici...

Palatin Technologies, Inc.

Palatin Technologies, Inc. is a biopharmaceutical company dedicated to the development of peptide, peptide mimetic and small molecule agonists with a focus on melanocortin and natriuretic peptide receptor systems. Palatin's internally developed drug pipeline utilizes proprietary approaches to discover potent rigid conformers from flexible peptide starting points. Palatin's strategy is to develop p...

Oncomatrix

Oncomatrix is focused on the development of new biopharmaceuticals targeting the tumor stroma. This innovative approach aims not to attack the tumor cells directly but rather the cells supporting the growth and invasiveness of the tumor.

National Brain Tumor Society (NBTS)

National Brain Tumor Society is the largest nonprofit organization dedicated to the brain tumor community in the United States. We are fiercely committed to finding better treatments, and ultimately a cure, for people living with a brain tumor today and those who will be diagnosed tomorrow. This means aggressively driving strategic research and advocati...


More From BioPortfolio on "A Pilot Study of Tumor-Specific Peptide Vaccination and IL-2 With or Without Autologous T Cell Transplantation in Recurrent Pediatric Sarcomas"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks